Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for PONV in Oncologic Patients
NCT03631004Phase 3Completed
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Olanzapine with Placebo (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting. Started Oct 2018; status: completed.
02
Drugs
olanzapine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT03631004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631004.